Investigation of Zymergen Inc.
Zymergen Inc. (ZY) Made Misstatements Regarding its Business Prospects Zymergen held its IPO on April 23, 2021, raising approximately $530.1 million. On August 3, 2021, Zymergen issued a business update
Zymergen Inc. (ZY) Made Misstatements Regarding its Business Prospects Zymergen held its IPO on April 23, 2021, raising approximately $530.1 million. On August 3, 2021, Zymergen issued a business update
Kanzhun Limited (BZ) Misled the Investing Public Regarding Its Cybersecurity Risks On July 5, 2021, Kanzhun announced that it was “subject to cybersecurity review by” the Cyberspace Administration of
Orphazyme A/S (ORPH) Misstated the Efficacy of its Drug Arimoclomal in its IPO Offering Documents Orphazyme held a public offering in September 2020 based on negligently prepared offering documents.
James River Group Holdings, Ltd. (JRVR) Misled the Investing Public Regarding the Impact of Uber on the Company’s Reserves In 2014, James River entered into a novel agreement with
Home Point Capital Inc. (HMPT) Made Misstatements in its IPO Offering Documents According to the class action complaint asserting claims under the Securities Act of 1933, Home Point conducted its
Oatly Group AB (OTLY) Made Misleading Statements in its Registration Statement in Connection with its Initial Public Offering Oatly held its initial public offering (“IPO”) on May 20, 2021,
Tarena International, Inc. (TEDU) Made Misstatements Regarding its Accounting Practices During the class period, defendants made false and misleading statements and/or failed to disclose that: (1) certain employees were
RenovaCare, Inc. (RCAR) Had Defective Disclosure Controls and Procedures that Caused its Stock Price to be Materially Inflated On May 28, 2021, the SEC issued a release stating it
CorMedix Inc. (CRMD) Failed to Disclose Deficiencies in the Manufacturing Process of its Lead Product Candidate CorMedix completed submission of a New Drug Application (“NDA”) to the U.S. Food and
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.